As a result, Figures 4A, B suggests that ZNF419 expression was associated with most immune checkpoint genes and immunoregulatory genes in BLCA, LUSC, KIRC, STES, LIHC, and even in PRAD, which was dubbed the “cold” tumor due to its passive immune profile and poor immunotherapy efficacy. The gene discussed is ZNF419; the disease is bladder transitional cell carcinoma.